<DOC>
	<DOCNO>NCT01275664</DOCNO>
	<brief_summary>This clinical trial study well granisetron , aprepitant , dexamethasone work prevent nausea vomit patient receive chemotherapy stage II , stage III , stage IV ovarian cancer . Granisetron patch , aprepitant dexamethasone may help lessen prevent nausea vomit patient receive chemotherapy stage II , stage III , stage IV ovarian cancer .</brief_summary>
	<brief_title>Granisetron , Aprepitant , Dexamethasone Preventing Nausea Vomiting Patients Receiving Chemotherapy Stage II , III , IV Ovarian Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine frequency chemotherapy-induced nausea vomit base complete response ( vomit use rescue therapy ) 6 day follow intraperitoneal ( IP ) chemotherapy 3-day regimen aprepitant ( injection capsule ) combination granisetron transdermal system dexamethasone ovarian cancer patient receive IP cisplatin OR IP carboplatin . SECONDARY OBJECTIVES : I . To evaluate possible endpoint chemotherapy-induced nausea vomiting , include : - Functional Living Index-Emesis ( FLIE ) questionnaire score - Mean vomiting , nausea total FLIE score change baseline FLIE score - Percentages patient impact daily living ( NIDL ) , i.e . &gt; 108/126 total FLIE score II . To describe time nausea vomit may guide modification standard regimen . OUTLINE : This multicenter study . Patients apply one patch granisetron transdermal system upper outer arm day 0 ( least 24 hour intraperitoneal [ IP ] platinum therapy ) . Patients receive dexamethasone orally ( PO ) day 1-4 , aprepitant IV 15 minute day 1 ( 30 minute IP platinum therapy ) , aprepitant PO day 2-3 . Patients complete Functional Living Index -- Emesis ( FLIE ) symptom diary baseline day 3 6 .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Endometrioid</mesh_term>
	<mesh_term>Cystadenocarcinoma</mesh_term>
	<mesh_term>Brenner Tumor</mesh_term>
	<mesh_term>Cystadenocarcinoma , Serous</mesh_term>
	<mesh_term>Cystadenocarcinoma , Mucinous</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Granisetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<criteria>Diagnosis ovarian epithelial , fallopian tube , primary peritoneal carcinoma Stage II , III , IV disease optimal ( = &lt; 1 cm residual disease ) suboptimal residual disease All patient must procedure determine diagnosis epithelial ovarian , fallopian tube , primary peritoneal , appropriate tissue histologic evaluation The minimum surgery require abdominal surgery provide tissue histologic evaluation establish document primary site stage , well maximal effort tumor debulking ; additional surgery perform , accordance appropriate surgery ovarian peritoneal carcinoma describe Gynecologic Oncology Group ( GOG ) Surgical Procedures Manual Patients follow histologic epithelial cell type eligible : Serous adenocarcinoma , endometrioid adenocarcinoma , mucinous adenocarcinoma , undifferentiated carcinoma , clear cell adenocarcinoma , mixed epithelial carcinoma , transitional cell carcinoma , malignant Brenner 's Tumor , adenocarcinoma otherwise specify ( N.O.S . ) However , histologic feature tumor must compatible primary MÃ¼llerian epithelial adenocarcinoma ; doubt exist , recommend investigator slide review independent pathologist prior entry Patients may coexist endometrial cancer long primary origin invasive tumor ovarian peritoneal clarification synchronous primary endometrial cancer Patients receive initial course chemotherapy include Paclitaxel 135 mg/M2 IV 3 hour day 1 Cisplatin 75 mg/M2 IP day 2 OR Paclitaxel 80 mg/m2 IV day 1 , 8 15 Carboplatin AUC 6 IP day 1 Prothrombin time ( PT ) international normalize ratio ( INR ) &lt; 1.5 x ULN ( inrange INR , usually 2 3 , patient stable dose therapeutic warfarin ) Partial thromboplastin time ( PTT ) &lt; 1.5 time upper limit normal ( heparin , lovenox alternative anticoagulant acceptable ) Patients GOG Performance Status 0 , 1 , 2 Patients able read , understand write English ; FLIE translate language , validate , become available , patient speak language enrol translation symptom diary arrange dependent availability suitable translator Patients able complete assessment Patients able comply antiemetic therapy Patients must meet preentry requirement Patients must sign approve informed consent authorization permit release personal health information Patients know hypersensitive aprepitant , granisetron component patch dexamethasone Patients receive prior radiotherapy portion abdominal cavity pelvis exclude ; prior radiation localize cancer breast , head neck , skin permit , provide complete three year prior registration , patient remain free recurrent metastatic disease Patients receive prior chemotherapy abdominal pelvic tumor include neoadjuvant chemotherapy ovarian primary peritoneal cancer exclude ; patient may receive prior adjuvant chemotherapy localize breast cancer , provide complete three year prior registration , patient remain free recurrent metastatic disease Patients pregnant nursing ; date , fetal study animal human perform ; possibility harm fetus likely Patients clinical symptom sign gastrointestinal obstruction and/ require parenteral hydration and/or nutrition ; patient history current diagnosis inflammatory bowel disease eligible Patients medical history condition otherwise previously specify opinion investigator exclude participation study ; example would hear loss neuropathy would prevent tolerance cisplatin , paclitaxel administration ; investigator feel free consult Study Chair Study CoChairs uncertainty regard Patients , opinion treat physician , medical condition , currently take medication , felt contraindicate safe effective administration standard three drug antiemetic regimen use study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>